Lin Zhou1, Jian Li1, Yaping Tang1, Mei Yang2. 1. Departmemt of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China. 2. Department of Geriatric Medicine, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Kaifu District, Changsha, Hunan, 410008, People's Republic of China. kyoym0131@sina.com.
Abstract
BACKGROUND: Cancer-associated fibroblasts (CAFs) play a pivotal role in regulating tumor progression by transferring exosomes to adjacent cells. Our aim was to clarify the role of LINC00659 encapsulated in CAFs-derived exosomes (CAFs-exo) in colorectal cancer (CRC). METHODS: CAFs and normal fibroblasts (NFs) were isolated and cultured. CAFs-exo and NFs-derived exosomes (NFs-exo) were characterized by transmission electron microscope and Western blot. The mRNA level of LINC00659 in CAFs-exo and NFs-exo were measured. Then we analyzed cell proliferation by CCK-8 and clone formation assay, cell migration by cell scratch, and cell invasion by Transwell. Epithelial mesenchymal transformation (EMT) related markers E-cadherin, N-cadherin, Vimentin and Snail-1 expressions were assessed by Western blot. The binding of LINC00659 and miR-342-3p, miR-342-3p and ANXA2 were analyzed by dual-luciferase reporter gene assay. RESULTS: CAFs and NFs showed a spindle-like morphology. CAFs-exo promoted CRC cell proliferation, migration, invasion and EMT progression. The expression of LINC00659 in CAF-derived exosomes was significantly increased, and fibroblasts could transfer exosomal LINC00659 to CRC cells. We further revealed that transfection of miR-342-3p mimic or sh-ANXA2 could obviously reverse the promotion effect of exosomal LINC00659 on CRC progression. Functional studies reveal that LINC00659 is transferred from CAFs to the cancer cells via exosomes, where it promotes CRC cell proliferation, invasion, migration and EMT progression in vitro. Mechanistically, LINC00659 interacts directly with miR-342-3p to increase ANXA2 expression in CRC cells. CONCLUSION: Collected evidence supported that CAFs-derived exosomal LINC00659 promotes CRC cell proliferation, invasion and migration via miR-342-3p/ANXA2axis.
BACKGROUND: Cancer-associated fibroblasts (CAFs) play a pivotal role in regulating tumor progression by transferring exosomes to adjacent cells. Our aim was to clarify the role of LINC00659 encapsulated in CAFs-derived exosomes (CAFs-exo) in colorectal cancer (CRC). METHODS: CAFs and normal fibroblasts (NFs) were isolated and cultured. CAFs-exo and NFs-derived exosomes (NFs-exo) were characterized by transmission electron microscope and Western blot. The mRNA level of LINC00659 in CAFs-exo and NFs-exo were measured. Then we analyzed cell proliferation by CCK-8 and clone formation assay, cell migration by cell scratch, and cell invasion by Transwell. Epithelial mesenchymal transformation (EMT) related markers E-cadherin, N-cadherin, Vimentin and Snail-1 expressions were assessed by Western blot. The binding of LINC00659 and miR-342-3p, miR-342-3p and ANXA2 were analyzed by dual-luciferase reporter gene assay. RESULTS: CAFs and NFs showed a spindle-like morphology. CAFs-exo promoted CRC cell proliferation, migration, invasion and EMT progression. The expression of LINC00659 in CAF-derived exosomes was significantly increased, and fibroblasts could transfer exosomal LINC00659 to CRC cells. We further revealed that transfection of miR-342-3p mimic or sh-ANXA2 could obviously reverse the promotion effect of exosomal LINC00659 on CRC progression. Functional studies reveal that LINC00659 is transferred from CAFs to the cancer cells via exosomes, where it promotes CRC cell proliferation, invasion, migration and EMT progression in vitro. Mechanistically, LINC00659 interacts directly with miR-342-3p to increase ANXA2 expression in CRC cells. CONCLUSION: Collected evidence supported that CAFs-derived exosomal LINC00659 promotes CRC cell proliferation, invasion and migration via miR-342-3p/ANXA2axis.
Authors: Mireia Berdiel-Acer; Rebeca Sanz-Pamplona; Alexandre Calon; Daniel Cuadras; Antoni Berenguer; Xavier Sanjuan; Maria José Paules; Ramon Salazar; Victor Moreno; Eduard Batlle; Alberto Villanueva; David G Molleví Journal: Mol Oncol Date: 2014-05-06 Impact factor: 6.603
Authors: J L Hu; W Wang; X L Lan; Z C Zeng; Y S Liang; Y R Yan; F Y Song; F F Wang; X H Zhu; W J Liao; W T Liao; Y Q Ding; L Liang Journal: Mol Cancer Date: 2019-05-07 Impact factor: 27.401
Authors: Julio César Villegas-Pineda; Mélida Del Rosario Lizarazo-Taborda; Adrián Ramírez-de-Arellano; Ana Laura Pereira-Suárez Journal: Front Cell Dev Biol Date: 2021-11-29
Authors: Ba Da Yun; Ye Ji Choi; Seung Wan Son; Gabriel Adelman Cipolla; Fernanda Costa Brandão Berti; Danielle Malheiros; Tae-Jin Oh; Hyo Jeong Kuh; Soo Young Choi; Jong Kook Park Journal: Int J Mol Sci Date: 2022-01-15 Impact factor: 5.923
Authors: Maria Radanova; Galya Mihaylova; Oskan Tasinov; Desislava P Ivanova; George St Stoyanov; Neshe Nazifova-Tasinova; Rostislav Manev; Ayshe Salim; Miglena Nikolova; Diana G Ivanova; Nikolay Conev; Zhasmina Mihaylova; Ivan Donev Journal: Int J Mol Sci Date: 2021-12-10 Impact factor: 5.923